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Abstract. Background: There is dire need for discovery of
novel pancreatic cancer biomarkers and of agents with the
potential for simultaneous diagnostic and therapeutic capacity.
This study demonstrates calreticulin expression on hamster
pancreatic adenocarcinoma via bio-conjugated gold quantum
dots (AuQDs). Materials and Methods: Hamster pancreatic
adenocarcinoma cells were cultured, fixed and incubated with
fluorescent AuQDs, bio-conjugated to anti-calreticulin
antibodies. Anti-calreticulin and AuQDs were produced in-
house. AuQDs were manufactured to emit in the near-infrared.
Cells were further characterized under confocal fluorescence.
Results: AuQDs were confirmed to emit in the near-infrared.
AuQD bio-conjugation to calreticulin was confirmed via dot-
blotting. Upon laser excitation and post-incubation with bio-
conjugated AuQDs, pancreatic cancer cell lines emitted
fluorescence in near-infrared. Conclusion: Hamster pancreatic
cancer cells express calreticulin, which may be labelled with
AuQDs. This study demonstrates the application of
nanoparticle-based theranostics in pancreatic cancer. Such
biomarker-targeting nanosystems are anticipated to play a
significant role in the management of pancreatic cancer.
Pancreatic cancer is a formidable disease, with rising incidence.
Patients usually experience no detectable symptoms until the
cancer has spread to other organs. Only about 10% of exocrine
pancreatic malignancies are contained within the pancreas at
the time of diagnosis and only about half of these prove to be
resectable (1). In England and Wales, only 1% of people
diagnosed with pancreatic malignancy survive for 10 years (2).
Without surgical resection median survival is 2 to 6 months and
estimated 5-year survival is 0.4 to 5% (3). Chemotherapy
improves pancreatic cancer survival only marginally (4).
Surgical resection is the only possible curative treatment;
however, only 10 to 15% of patients are candidates for curative
resection upon their initial presentation. Moreover,
pancreatectomies are associated with considerable morbidity
and mortality rates outside specialising centres, even though in
high-volume centres these lie between 3% and 5% (5).
There is currently dire need for gaining further insight into
pancreatic carcinogenesis in order to identify biomarkers for
cystic and solid pancreatic lesions and for resourcing novel
ways of tackling the disease. One potential biomarker is
calreticulin, a ubiquitous Ca2+-binding protein with chaperone
activity, which is highly conserved among species. Calreticulin
resides in the endoplasmic reticulum. It is also found in the
nucleus, suggesting that it may have a role in transcriptional
regulation. It has three domains (6), each responsible for a
different function, namely calcium binding (7), chaperoning
(8), integrin binding and steroid hormone receptor modulation.
Calreticulin expression has been positively correlated with
various types of cancer (9), including pancreatic (10). Not only
is calreticulin overexpressed in pancreatic cancer, but it also
contributes to its progression; it has been shown that its
expression is positively correlated with tumour International
Union Against Cancer stage and lymphatic metastasis status
(11). It has further been demonstrated that calreticulin is
expressed on the cell surface in various human cancer types,
including bladder, ovarian and brain cancer, conferring worse
clinical prognosis (12). However, calreticulin expression on the
surface of pancreatobiliary cancerous cells is yet to be proven.
Perhaps contrary to the above, calreticulin appears to promote
immunogenic cell death by modulating cytotoxic lymphocytic
activity (12) and promoting cancerous cell phagocytosis (13).
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Calreticulin seems to be translocated to the cancer cell surface,
becoming the dominant pro-phagocytic signal for cancer cell
death (12); notably, this latter study did not include pancreatic
tissue specimens, hence calreticulin cell-surface expression on
dysplastic or cancerous pancreatic cells is yet to be proven.
Quantum dots (QD), or nanocrystals, are semiconductor
crystal structures of nanoscale dimensions (2-10 nm). They are
made of semiconductor materials that are small enough to
exhibit quantum mechanical properties. Their electronic
properties are intermediate between those of bulk
semiconductors and discrete molecules.
Due to their size, semiconductor QD nanoparticles bear
unique optical properties, such as highly tuneable fluorescence,
sharp emission spectra, high quantum yield and remarkable
photostability (14). Apart from these characteristics, their
relatively large surface-to-mass ratio allows them to bind and
adsorb compounds, such as antibodies, peptides, probes or drugs.
These attributes provide QDs with a unique potential for a huge
range of applications, ranging from tagged biomarker
development for cancer detection or precancerous screening, to
targeted treatments with drug delivery, cancer vaccinations or
tissue labelling prior to resection. QDs also have great potential
in photodynamic therapy, where they act as either
photosensitizers themselves or as carriers. All that being said,
QD-based drug delivery has been relatively less investigated,
largely due to the potential innate toxicity of QDs. This problem
is more prominent with the first-generation QDs, where toxic Cd
and Pb were frequently used in QD preparation. These elements
are prone to produce toxic products upon photo-oxidation. It is,
therefore, necessary to manufacture QDs from less toxic metals
in order to facilitate their safe in vivo application as theranostic
agents. One potentially suitable element is gold (Au).
The aim of this study was twofold: to demonstrate
calreticulin expression in hamster pancreatic adenocarcinoma;
and to demonstrate the development of gold nanoparticles and
their successful bio-conjugation to rabbit polyclonal antibodies
to calreticulin (calreticulin pAbs).
Materials and Methods
AuQDs, as well as calreticulin synthetic peptide and anti-calreticulin
polyclonal antibodies, were all produced at the laboratory of the
Surgery Research Department of the University College of London, at
the Royal Free Campus. The AuQDs were manufactured to emit in
near infra-red (NIR). The size and pattern of these QDs were further
characterised with the use of transmission electron microscopy. Anti-
calreticulin pAb specificity was confirmed with competitive inhibition
assay. The anti-calreticulin antibodies were bio-conjugated to the
AuQDs, which was confirmed by dotblotting.
Syrian golden hamster (GN strain) pancreatic adenocarcinoma cell
lines (HaP-T1) originating from Japan (University College London
Biobank) were cultured at the tissue culture laboratory at the Surgery
Research Department of the University College of London. Cells were
cultured in six-well plates, which were then washed with phosphate-
buffered saline (PBS). Cells in half of the wells were then incubated
with calreticulin pAb-conjugated AuQDs. The HaP-T1 colonies not
exposed to calreticulin pAbs served as controls. Samples of these cell
lines were then fixed on slides and viewed under laser scanning
confocal microscopy. The images obtained underwent qualitative and
quantification analysis, based on the pixel intensity of luminance
(ImageJ 2.0.0-rc-9;’National Institutes of Health, Bethesda, MD,
USA). Continuous digital data obtained were statistically analysed via
Wilcoxon signed-ranks test (Wilcoxon Signed-Ranks Test Calculator,
Social Statistics Web).
AuQD synthesis. QDs used in this project were produced in-house
(Cancer Nanotechnology Group/University College London),
assembled via a simple nanoparticle synthesis route, based on gold
as core metal element and mercaptosuccinic acid (MSA) as
stabilising and coating agent (Ramesh B, Giorgakis E, Lopez-
Davila V, Kamali-Dashtarzheneha A, Loizidou M, unpublished
observations). In brief, the method involved using a borate/citrate
buffer at 25 mM at pH 6.5. Instead of using sodium
tetrahydridoborate as a reducing agent in the formation of QDs,
200 μm of dimethylformamide was introduced as a reductant into
the buffer whilst mixing vigorously. This mixture was then exposed
to hydrothermal treatment (autoclave) at 121˚C for 25 minutes to
give QDs with near infrared (NIR) emission at >800 nm. The
water-soluble NIR-emitting QDs obtained were further
characterised using spectrophotometric analysis. The size and
pattern of these QDs were further confirmed by transmission
electron microscopy. These nanocrystals were configured in the
form of crystals or clusters, measuring in the range of 2 μm.
Production of anti-calreticulin synthetic peptide IgG antibodies. The
AuQDs produced were bio-conjugated with calreticulin pAbs prior to
pancreatic cell calreticulin targeting. This required the generation of
anti-serum to human calreticulin. A 15 amino-acid peptide
corresponding to calreticulin amino-terminus was synthesised in-house
(Ramesh B, Giorgakis E, Lopez-Davila V, Kamali-Dashtarzheneha A,
Loizidou M, unpublished observations). This peptide was coupled to a
protein carrier. The protein carrier used was Keyhole Limpet
haemocyanin (KLH) (Sigma-Aldrich Company Ltd, Poole, Dorset,
UK), which was then coupled to the calreticulin peptide with the
addition of glutaldehyde. This yielded KLH-conjugated calreticulin
peptide which was then used as an antigen for rabbit immunisation. It
was injected into New Zealand white rabbits (intramuscular, 1
mg/rabbit) for calreticulin pAb production. Anti-calreticulin IgG was
purified by precipitation with ammonium sulphate.
Calreticulin pAb conjugation to AuQDs. Anti-calreticulin produced as
described above was then conjugated to AuQD nanoparticles.
Fluorescent AuQD/Au/MSA QD solution was diluted with equal
volume of cold ethanol and centrifuged at 1.5 g for 30 minutes. The
precipitated Au/MSA QDs were vacuum dried to obtain a dry metal
complex. The precipitated dried QDs (approximately 1 mg) were re-
suspended in 1 ml PBS. The obtained solution of coated QDs (1 ml)
was immuno-conjugated to the rabbit calreticulin pAb using 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) as an acylating agent.
EDC was used in combination with N-hydroxysuccinimide (NHS).
Briefly, 200 ml QD/MSA solution (1 mg/ml) was mixed with 200 ml
EDC (1 mg/ml) and 200 ml NHS (1 mg/ml) in PBS for 30 minutes at
room temperature before adding 100 ml of calreticulin pAb solution
(5 mg/ml) to the mixture and mixing for 1 hour at room temperature.
To separate the reagent and unconjugated AuQDs, membrane
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centrifugal columns (Centricon Thermo Fisher Scientific, Waltham,
MA, USA) with a cut-off of 100 kDa with UV monitoring at 280 nm
of the retained samples was used. The purified Au/MSA QDs
conjugated to calreticulin pAbs were collected and stored at 4˚C until
further use.
DotBlot confirmation of calreticulin synthetic peptide conjugation to
AuQDs. AuQD– calreticulin pAb binding to calreticulin synthetic
peptide was demonstrated by dot-blotting. In brief, 5 μl of 1:1000
dilution of AuQD-calreticulin pAb (1 mg/ml) in water was blotted
onto aqueous equilibrated polyvinyldiflouride (PVDF) membrane
(Hybond P; Amersham Pharmacia Biotech, Bucks, UK) and allowed
to dry at room temperature. The membrane was then rinsed briefly in
PBS with 0.05% Tween 20 (PBS/T; pH 7.4) and incubated overnight
at room temperature in 2% bovine serum albumin with 0.005%
sodium azide for blocking any residual binding sites on the
membrane. This was followed by three further rinses (5 minutes
each) with PBS/T prior to application of anti-rabbit monoclonal IgG
horse radish peroxidase (HRP)-conjugated Ab (Amersham ECL
Rabbit IgG, HRP-linked whole donkey Ab, from GE Healthcare Life
Sciences, GE Healthcare UK Limited, Amersham Place,
Buckingham shire, UK) and left to incubate at room temperature for
one hour (1:5000 dilution, as recommended by the manufacturer).
HRP-conjugated anti-rabbit monoclonal IgG would detect
AuQD–calreticulin pAb, validating primary antibody conjugation.
Following five further rinsing steps with PBS/T (of 5 minutes each),
the polyvinylidene difluoride membrane was developed using
SuperSignalR West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific) detection of the dot blots. Chemiluminescence was
detected by gel documentation instrument (BIO-RAD, Molecular
ImagerR Chemic DocTm XRS+, Bio-Rad, Hercules, CA, USA)
AuQD fluorescence was also detected by the instrument using
ultraviolet (UV) excitation and longpass (LP) filters. 
Hamster Syrian pancreatic adenocarcinoma cell line (HaP-T1)
culture. This cell line was derived from a Syrian golden hamster (GN
strain) pancreatic adenocarcinoma (Sigma Aldrich Co. LLC, Toyama
Medical and Pharmaceutical University, Toyama, Japan). The cells
were cultured in six well plates in 5% CO2 Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% foetal bovine
serum, penicillin (10,000 units/ml), streptomycin (10,000 μg/ml), 1
mM pyruvate, 2 mM glutamine and 10 mM N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic acid (Gibco® HEPES,
Thermo Fisher Scientific). Cells were seeded at 106 per well and
incubated for 24 hours. After that time, the cells were washed with
PBS (pH 7.4) and fixed with 4% paraformaldehyde solution for 1 hour
at room temperature. Cells were washed three times with PBS. They
were incubated with calreticulin pAb-conjugated AuQDs in PBS with
0.6% bovine serum albumin for 1 hour and were then washed three
times with PBS. Hap-T1 colonies in the cell culture plate wells not
exposed to AuQD–calreticulin pAbs served as controls.
Laser scanning confocal fluorescent microscopy (LSCM). The
paraformaldehyde fixed slides of hamster pancreatic cell lines were
viewed under an LSCM (Nikon Eclipse TE 300, Nikon, Chiyoda,
Tokyo City, Tokyo, Japan). The slides were illuminated with 488
nm laser and filtered with 650/LP barriers. Since the AuQDs used
were designed to emit in the near infrared (beyond 800 nm), which
is difficult to visualise without an NIR camera, their mapped red
blue green (RBG) images were captured in the red pseudo-colour
spectral band. 
Statistical analysis. The digital photomicrographs of HaP-T1 cell lines
were further analysed with the use of FIJI (ImageJ 2.0.0-rc-9, National
Institutes of Health). Histograms were developed for all captures taken
with the use of LSCM (Nikon TE 300) under excitation with a 488
nm laser beam and passage through 650 nm/LP filter in order to plot
the tonal distribution of the respective digital images. The digital data
obtained were subjected to statistical interpretation. Specifically, the
pixel tone medians derived from the digital images’ quantification
analysis (ImageJ 2.0.0-rc-9) of HaP-T1 cell plates were compared for
testing the hypothesis that the medians of pixel tone between images
of AuQD-calreticulin pAb exposed HaP-T1 cell lines vs. HaP-T1
controls were identical. The statistical method used was single-tailed
Wilcoxon signed-ranks test (Wilcoxon Signed-Ranks Test Calculator,
Social Statistics Web). The level of significance was set to p<0.05.
Results
Dot-blotting. By dot-blot incubating of progressive dilutions of
AuQD–calreticulin in the presence of anti-rabbit HRP-
conjugated Ab, it was demonstrated that the calreticulin pAb
was bound to the AuQDs (Figure 1a). The same blots emitted
progressively decreasing fluorescence on excitation with UV
which was detected with the use of LP filters (Figure 1b). This
decreasing chemiluminescence of the progressive dilutions of
AuQD–calreticulin pAb in the presence of HRP-conjugated
Abs demonstrated the presence of rabbit anti-calreticulin pAb
in the blots. Likewise, the decreasing fluorescence under UV
excitation during progressive dilution demonstrated the
presence of AuQD fluorophores in the same blots.
LSCM (Figure 2). After He-Ne laser excitation, the HaP-T1
cells that had undergone incubation with AuQD–calreticulin
pAbs emitted in the NIR. Fluorescence emission of Hap-T1
cells not incubated with calreticulin pAb-conjugated AuQD
excitation under the same wavelength light was only limited to
background noise. This significantly increased NIR fluorescence
of the cancerous cells incubated with calreticulin pAb and could
be only related to the binding of the AuQD–calreticulin pAb
fluorophores, indicating the presence of calreticulin on the
surface and/or the extracellular milieu of the pancreatic
cancerous cells. Perhaps as expected, HaP-T1 fluorescence was
uniform, apart from some areas of ground-glass luminescence,
probably indicatory of more densely-packed cellular material or
cellular lysis with resultant higher levels of unbound
calreticulin. Note was also made of rounded highly fluorescent
areas in the wells that had been treated with conjugated AuQDs,
which might be representative of AuQD congregations.
The significantly increased NIR fluorescence of HaP-T1 cell
lines after exposure to AuQD–calreticulin pAbs provides
evidence of calreticulin pAb binding to the fixed hamster
pancreatic adenocarcinoma cells, which could only be possible
in the presence of calreticulin in the surface or the extracellular
milieu of the cancerous cells.
Quantification of digital images demonstrated that the
tone distribution of HaP-T1 cells in incubated with
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AuQD–calreticulin pAb was different from that of its paired
control. This demonstrated that HaP-T1 retained
AuQD–calreticulin pAbs, which further shows that hamster
pancreatic adenocarcinoma expresses calreticulin.
The experiments on hamster pancreatic adenocarcinoma cell
lines (HaP-T1) lead to the conclusions that: Hamster Syrian
pancreas adenocarcinoma can be labelled on fixed tissue
sections with AuQDs, bio-conjugated with rabbit pAbs to
human calreticulin; hamster Syrian pancreatic adenocarcinoma
expresses calreticulin; and calreticulin is expressed in the
extracellular milieu of the cancerous cells.
Discussion
Pancreatic cancer survival has not shown much improvement
in the last 40 years. It is an almost uniformly fatal cancer, with
an incidence rate approaching its mortality rate (1), reflecting
the inadequacy of current treatments (16). Chemotherapy
improves pancreatic cancer prognosis only marginally (5),
leaving surgical resection as the only curative option. Since
long-term survival can only be achieved with R0 resection (17),
pancreatectomy is currently the cornerstone of pancreatic
cancer treatment.
The aim of this study was to demonstrate that calreticulin is
expressed on the surface of hamster pancreatic adeno-
carcinoma. The chosen means for calreticulin targeting were
AuQDs. AuQDs, as well as the rabbit pAbs to calreticulin and
AuQD–calreticulin pAb bio-conjugation, were all developed
in-house by the Cancer Nanotechnology Group (Ramesh B,
Giorgakis E, Lopez-Davila V, Kamali-Dashtarzheneha A,
Loizidou M, unpublished observations). Cellular surface
calreticulin-QD labelling has been demonstrated elsewhere
(12); however, in previous studies, the nanocrystals had Cd as
core element and the cells were non-cancerous (12). Therefore,
this was the first demonstration of calreticulin expression in
hamster pancreatic adenocarcinoma.
The justification of semiconductor nanocrystal use as
fluorophores for calreticulin molecular labelling was twofold:
firstly, because QDs are known favourable alternatives to
conventional organic dye fluorophores due to their “intrinsic
robustness, high photostability, spectrum tunability, broad
absorption spectra and narrow emission peaks’’ (17), QDs have
demonstrated their capability to image fixed cells with “intense
brightness, prolonged fluorescence and no photo bleaching’’
(17). The second reason was because a demonstration of
AuQD–calreticulin conjugation in pancreatic malignancy may
pave the way for numerous screening, diagnostic and
therapeutic applications on pancreatic cancer.
The fixed HaP-T1 hamster pancreatic cancer cell cultures
were characterised under confocal fluorescence before and after
incubation with AuQD–calreticulin pAb. The fixed cells emitted
high NIR fluorescence after incubation with AuQD–calreticulin
pAb and 488 nm excitation, demonstrating that they had
retained AuQD–calreticulin pAbs. This means that calreticulin
was present on the surface of hamster pancreatic
adenocarcinoma cells. Note was made of areas with ground-
glass appearance with more luminescence, probably indicating
the presence of more densely packed cellular material. Note was
also made of rounded highly fluorescent areas in the wells
treated with conjugated AuQDs, perhaps representing AuQD
congregations. The increased NIR fluorescence of HaP-T1 cell
lines after exposure to AuQD–calreticulin pAb strongly supports
the hypothesis of calreticulin cell surface translocation in
hamster pancreatic adenocarcinoma; similar findings have been
observed in human cancer cell lines (Ramesh B, Giorgakis E,
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Figure 1. Dot blot of gold quantum dot (AuQD)-calreticulin polyclonal
antibodies (pAbs) in the presence of anti-rabbit horseradish peroxidase-
conjugated antibody. In progressive dilutions (left to right: 1:10, 1:100,
1:1,000 and 1:10,000), of AuQD–calreticulin pAbs, the blots produced
decreasing chemiluminescence (a). Likewise, under UV light, the gelDoc
detected decreasing UV fluorescence in the same dilutions, thus
demonstrating the presence of the fluorescent AuQDs (b). As described
in the Materials and Methods section, the AuQDs used on these
experiments had been manufactured to emit in the near infra red.
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Figure 2. Composite image of digital photomicrographs of hamster pancreatic cancer cells. All images in the right column were taken from wells
exposed to gold quantum dot (AuQD)-calreticulin polyclonal antibodies (pAbs). a, b: Differential interference contrast (DIC) captures. d, f: After
excitation with 488 nm laser beam and passage through 650/longpass. c, e: DIC/fluorescence overlay. The increased NIR fluorescence of HaP-T1
cells after exposure to AuQD–calreticulin pAbs provides evidence of calreticulin cell-surface expression in hamster pancreatic adenocarcinoma.
Lopez-Davila V, Kamali-Dashtarzheneha A, Loizidou M,
unpublished observations). 
Digital image data quantification analysis of HaP-T1
demonstrated a shift of the tone plot distribution towards the
right hand-side and broader tonal distribution after AuQD-
labelling, implying that the images were becoming more
fluorescent after AuQD–calreticulin pAb exposure, meaning
that the cells had bound or trapped AuQD bio-conjugates,
something which would only be feasible in the presence of
calreticulin on the surface or in the extracellular milieu of the
cancerous cells. AuQD–calreticulin pAb uptake was further
demonstrated with digital subtraction of the images, which
resulted in sharper mapped RBG images after removal of the
background red/NIR fluorescence. Statistical analysis further
confirmed the significantly increased fluorescence of the
pancreatic cancer cell line in the NIR after incubation with
AuQD–calreticulin pAbs (p<0.05).
The finding of calreticulin expression in pancreatic neoplasia
and precancerous states has been reported elsewhere (11). Cell-
surface calreticulin expression in various types of human
cancer cells has already been described (12). According to the
Authors’ best knowledge, this study provides the first indication
of calreticulin cell -surface translocation in pancreatic ductal
adenocarcinoma.
Even though calreticulin cell-surface expression with the use
of QDs has been demonstrated elsewhere with the use of Cd
QDs (14), this is the first demonstration of calreticulin expression
in malignant cells with the use of QDs and specifically the first
demonstration of calreticulin labelling in hamster tissue with the
use of rabbit calreticulin pAbs conjugated to AuQDs. QDs have
been used in the past for labelling human pancreatic cancer cells
(19). Qian et al. had used Cedes/Cods/Zen’s QDs, coated with
lysine and anti-claudin-4 (pancreatic cancer-specific monoclonal
antibody) as a targeting ligand (20). The use of nanocrystals with
Au cores poses a lower toxicity risk (Ramesh B, Giorgakis E,
Lopez-Davila V, Kamali-Dashtarzheneha A, Loizidou M,
unpublished observations). Beyond this, given the known
calreticulin expression in various types of human cancer, bio-
conjugated AuQDs might find application in targeting various
other calreticulin-positive lesions.
The use of QDs for biomedical application arises from their
unique physicochemical properties and their ability to serve as
scaffold for additional agents, such as targeting ligands and
therapeutic drugs. Gold-based nanoparticle agents have further
unique characteristics, such as strong surface absorption,
stability, biosafety, and ease of modification; for this reason,
gold-based nanoparticles have since long been exploited as a
candidate material for building up functional agents for both
imaging and therapeutic applications. Nonetheless, there is an
urgent need to understand the metabolism of AuQDs and
address any related toxicity issues (19). A potential
disadvantage of using AuQD diagnostic and therapeutic
platforms are their high cost of production.
Further in vivo studies need to be undertaken in order to
demonstrate selective calreticulin overexpression in human
pancreatic adenocarcinoma and replicate its in vivo targeting
with AuQDs. If calreticulin expression on pancreatic cancer is
confirmed in humans, AuQD–calreticulin pAbs can find
application in the in vivo fluorescence imaging of pancreatic
calreticulin-positive tumours: AuQD-labelled calreticulin
tracers may be injected into patients undergoing diagnostic
laparoscopy or pancreatic resection and then be surgically
explored under fluorescence or the frozen sections be reviewed
under NIR fluorescence in order to assess for metastatic
disease, local disease advancement, vascular infiltration or
resection margins.
Vohra et al. has already used spectral imaging to trace
intravenously injected tumour-labelled QDs into mice (19).
Intra-operative fluorescence imaging of colorectal and
pancreatic cancer with the use of anti-carcinoembryonic (CEA)
fluorophore-conjugated Abs has already been demonstrated
elsewhere (21). Metildi et al. have already demonstrated that
fluorescent-guided laparoscopic surgery (FGS) with the use of
fluorophore-conjugated chimeric anti-CEA Abs reduced the
recurrence rates and increased disease-free survival and cure
rates in an orthotopic mouse model of pancreatic cancer (22).
FGS appears to be superior in identifying metastatic disease if
compared to conventional laparoscopic surgery (23). Our study
demonstrated that calreticulin can be targeted with fluorophore-
conjugated calreticulin pAbs in fixed hamster pancreatic
cancerous cell lines. The above findings in conjunction indicate
that fluorophore-conjugated calreticulin pAbs can be employed
as an alternative GFS navigation tool, with AuQDs as the
conjugated fluorophore. The demonstrated superiority of FGS
in revealing occult metastatic deposits, in conjunction with the
overall dominance of QDs in terms of fluorescence emission
robustness, photostability and spectrum tunability indicate that
FGS with the use of QDs might be one of the ways forward in
laparoscopic hepatobiliary and pancreatic surgery, specifically
in staging laparoscopy. FGS with the use of AuQD
fluorophores is expected to reduce the rate of false-negative
staging laparoscopies, thus sparing patients from the sequelae
of a laparotomy for inoperable disease (24).
Apart from their utility as a higher fidelity surgical
navigation tool, AuQD-labelled calreticulin tracers could also
become nanoscale platforms for the delivery of anticancer
agents or for thermal ablation of cancerous cells (25, 26).
Conclusion
This project has demonstrated that calreticulin is expressed and
may be labelled on fixed cell lines on hamster pancreas ductal
adenocarcinoma, indicating calreticulin expression in hamster
pancreatic adenocarcinoma; this is in agreement with the
demonstration of calreticulin expression on human cancer cell
lines. It further demonstrated that AuQDs can be bio-
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conjugated to polyclonal antibodies to calreticulin, induced in
rabbit using a human calreticulin peptide analogue.
In theory, AuQDs can deliver therapeutic agents to a diseased
area and their unique physical properties be exploited to
improve diagnosis and monitor therapeutic response, since
AuQD nano-platforms can be relatively easily manipulated and
loaded with appropriate therapeutic agents. Nonetheless, despite
the progress in nanoparticle theranostics, there are disadvantages
to be overcome, such as QD toxicity and cost to name a few.
The findings of this study may open the gates for further
investigation of calreticulin expression in human pancreatic
cancer and on the application of QD-based theranostics in its
timely detection and treatment. Despite its promise, our
evidence-based insight is still far from adequate and our
preliminary findings should trigger further investigation in this
challenging yet highly inviting field.
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